What is the 13F Pro Quality Score for ALT?

13F Pro ranks Altimmune, Inc. (ALT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ALT's current score at https://13fpro.ai/research/ALT (free sign-up required for the full ranking).

Which hedge funds own the most ALT stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ALT include BlackRock,, STATE STREET, VANGUARD CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/ALT as soon as new 13F filings post.

Where does 13F Pro source ALT data?

All Altimmune, Inc. fundamentals and ownership data come directly from SEC EDGAR. Altimmune, Inc. files with the SEC under CIK 1326190. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ALT in?

Altimmune, Inc. (ALT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ALT research updated on 13F Pro?

ALT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Altimmune, Inc.(ALT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1326190 ALT stock profile & AI dashboard →

13F Pro Quality Score

7.3/100

Rank #2,837 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

0.2/100

Profitability

0.1/100

Balance Sheet

7.6/100

Earnings Quality

30.0/100

Free Cash Flow

0.1/100

Institutional Flow

91.7/100

Revenue Scale

0.1/100

Dilution Risk

0.1/100

ALT Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Altimmune, Inc. (ALT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ALT at 7.3/100 on a 32-signal composite quality model, placing it at rank #2,837 of 2,879 stocks — the bottom half of the AI-ranked universe. ALT scores in the top quartile across institutional flow (91.7). Areas of concern include profitability (0.1) and free cash flow (0.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Altimmune, Inc. reports net income of $-22.6M, free cash flow of $-21.0M. Top institutional holders of ALT by reported 13-F value include BlackRock,, STATE STREET, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. ALT trades on the Nasdaq exchange and files with the SEC under CIK 1326190. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ALT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Altimmune, Inc. directly from SEC EDGAR. Altimmune, Inc.'s 13F Pro composite quality score has ranged between 2 and 41 since 2021, currently 7.3 — an improving long-term trajectory across 34 quarterly and live scoring snapshots.

✦

Fun facts about Altimmune, Inc.

Quirks, history, and lore behind ALT — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in Maryland · focused on immunology and metabolic disease.
2
The Numbers
A small-cap company with minimal product revenue — it runs on grants, collaborations, and capital raises, as most clinical-stage biotechs do.
3
The History
Founded in the early 2000s, the company originally built its pipeline around intranasal vaccine technology before pivoting its focus toward obesity and liver disease.
4
The Secret
Its lead asset targets GLP-1 receptor agonism for obesity — putting it in the same crowded, very hot race as pharma giants many times its size.
5
The Lore
The company once had a government contract to develop an anthrax vaccine — not your typical biotech origin story — before chasing the weight-loss drug gold rush.
6
The Giveaway
Its obesity drug candidate pemvidutide is its crown jewel, and its three-letter ticker is also the word for "alternative" — fitting for a scrappy underdog swinging at Novo Nordisk.

▶ Think you know your stocks? Play the Daily Ticker

Net Income

Q1 2026

$-22.6M

Free Cash Flow

Q1 2026

$-21.0M

D/E Ratio

Q1 2026

0.12

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+726.5% YoY

$426.0KFY 2023

FY20 $8.2MFY21 $4.4MFY22 $-68.0KFY23 $426.0K

Net Income

-4.4% YoY

$-88.4MFY 2023

FY20 $-49.0MFY21 $-97.1MFY22 $-84.7MFY23 $-88.4M

Operating Income

-9.3% YoY

$-95.9MFY 2023

FY20 $-54.8MFY21 $-96.9MFY22 $-87.7MFY23 $-95.9M

EPS (Diluted)

+8.3% YoY

$-1.66FY 2023

FY20 $-1.91FY21 $-2.35FY22 $-1.81FY23 $-1.66

Total Assets

+1.8% YoY

$210.6MFY 2023

FY20 $245.1MFY21 $218.9MFY22 $206.9MFY23 $210.6M

Total Debt

—FY 2023

FY20 $1.8MFY21 $1.5MFY22 $4.6MFY23 —

Op. Cash Flow

-21.1% YoY

$-75.8MFY 2023

FY20 $-34.3MFY21 $-78.2MFY22 $-62.6MFY23 $-75.8M

Metric	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2017
Revenue	$426.0K +726.5%	$-68.0K -101.5%	$4.4M -46.1%	$8.2M +41.1%	$5.8M -46.0%	$10.7M
Net Income	$-88.4M -4.4%	$-84.7M +12.7%	$-97.1M -98.0%	$-49.0M -139.0%	$-20.5M +55.8%	$-46.4M
Operating Income	$-95.9M -9.3%	$-87.7M +9.5%	$-96.9M -76.9%	$-54.8M -155.3%	$-21.5M +58.8%	$-52.0M
EPS (Diluted)	$-1.66 +8.3%	$-1.81 +23.0%	$-2.35 -23.0%	$-1.91	—	—
Total Assets	$210.6M +1.8%	$206.9M -5.5%	$218.9M -10.7%	$245.1M +353.4%	$54.1M -14.2%	$63.0M
Total Debt	—	$4.6M +215.1%	$1.5M -20.5%	$1.8M -2.0%	$1.9M +210.9%	$599.9K
Operating Cash Flow	$-75.8M -21.1%	$-62.6M +20.0%	$-78.2M -128.1%	$-34.3M -257.3%	$-9.6M +52.5%	$-20.2M

AI Insight: ALT Financial Trends

Altimmune remains pre-revenue with mounting debt and equity dilution offsetting modest operating expense improvements.

• Operating income loss narrowed from $27M in Q2 2024 to $24M in Q1 2026, showing expense discipline despite zero revenue.

• Total debt surged from $14M in Q2 2025 to $35M in Q1 2026; equity grew to $284M, indicating reliance on capital raises.

• Operating cash burn moderated to $12M in Q3 2025 from $27M in Q3 2024, but rebounded to $21M by Q1 2026.

⚠ Equity nearly doubled from $153M (Q2 2024) to $284M (Q1 2026)—heavy shareholder dilution to fund pre-revenue operations.

⚠ Net loss deteriorated to $27M in Q4 2025, the worst quarter in the dataset; trajectory into 2026 warrants close monitoring.

AI Insight: ALT Ratio Trends

Altimmune showing dramatic improvement in ROIC and ROE, though all remain deeply negative—recovery trajectory still unproven at breakeven.

• ROIC improved from -80.5% in Q4 2024 to -30.4% in TTM 2026—nearly 50pp swing in profitability metrics.

• ROE recovered from -75.1% in Q4 2024 to -31.8% in Q1 2026, narrowing losses materially across the trailing year.

• Leverage remains minimal: D/E stable at 0.12 in TTM, down from peak 0.15 in Q4 2025.

⚠ Q1 2026 shows ROIC/ROE stalling at -30.4% and -31.8%—no sequential progress from Q3 2025 trough.

⚠ All profitability ratios remain substantially negative; company still unprofitable and burning capital.

Get alerted when ALT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Altimmune, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ALT

BlackRock, Inc.
$39.4M12,795,277 sh
STATE STREET CORP
$22.0M7,145,550 sh
VANGUARD CAPITAL MANAGEMENT LLC
$17.4M5,658,049 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$16.6M5,382,002 sh
MARSHALL WACE, LLP
$12.4M4,017,901 sh
MILLENNIUM MANAGEMENT LLC
$10.0M3,258,191 sh
GEODE CAPITAL MANAGEMENT, LLC
$9.6M3,107,096 sh
Alyeska Investment Group, L.P.
$8.1M2,644,600 sh
TWO SIGMA INVESTMENTS, LP
$7.6M2,478,900 sh
Nuveen, LLC
$7.2M2,334,601 sh

Fund	Value	Shares
BlackRock, Inc.	$39.4M	12,795,277
STATE STREET CORP	$22.0M	7,145,550
VANGUARD CAPITAL MANAGEMENT LLC	$17.4M	5,658,049
VANGUARD PORTFOLIO MANAGEMENT LLC	$16.6M	5,382,002
MARSHALL WACE, LLP	$12.4M	4,017,901
MILLENNIUM MANAGEMENT LLC	$10.0M	3,258,191
GEODE CAPITAL MANAGEMENT, LLC	$9.6M	3,107,096
Alyeska Investment Group, L.P.	$8.1M	2,644,600
TWO SIGMA INVESTMENTS, LP	$7.6M	2,478,900
Nuveen, LLC	$7.2M	2,334,601

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ALT on your watchlist

Track score changes the day Altimmune, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ALT a good stock to buy?

13F Pro's AI-powered analysis of Altimmune, Inc. (ALT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ALT are available on the ALT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ALT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ALT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Altimmune, Inc.'s investment landscape.